Pfizer’s twice-daily GLP-1 danuglipron reached its primary endpoint in a Phase 2b trial but caused high rates of side effects like nausea and vomiting.
‘It’s not about more weight loss.’ Have obesity drugmakers maxed out?
Among adults with established cardiovascular disease who were overweight or had obesity but did not have diabetes, weekly semaglutide cut the risk of major adverse cardiovascular events by 20%.
How Eli Lilly’s obesity drug Zepbound is poised to reshape pharma markets
Tirzepatide, the active ingredient in Lilly’s type 2 diabetes drug Mounjaro, has now been approved to treat obesity. What does it mean for the pharma industry?
Biolexis debuts subsidiary using AI to develop diabetes, weight loss drugs